Literature DB >> 30617092

Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016).

Cecilia G Carvalhaes1, Michael D Huband2, Harald H Reinhart3, Robert K Flamm2, Helio S Sader2.   

Abstract

Omadacycline is a derivative of minocycline and the first agent of the aminomethylcycline class. A total of 3,282 organisms (1 per patient) were consecutively collected from patients hospitalized in China (including Hong Kong) and Taiwan. Susceptibility testing was performed by broth microdilution methods in a central laboratory (JMI Laboratories). The collection included Gram-positive and Gram-negative organisms from patients with pneumonia, bloodstream, skin, community-acquired respiratory, and other infections. Omadacycline was very potent against Staphylococcus aureus (n = 689; MIC50/90, 0.12/0.25 mg/liter), including methicillin-resistant Staphylococcus aureus (MRSA; n = 299; MIC50/90, 0.12/0.5 mg/liter), and had similar activity across geographic regions. Omadacycline was very active against Streptococcus pneumoniae (highest MIC, 0.25 mg/liter), β-hemolytic streptococci (highest MIC, 1 mg/liter), viridans group streptococci (highest MIC, 0.25 mg/liter), and Enterococcus spp. (highest MIC, 0.5 mg/liter) from all geographic regions. Overall, 53.8% of S. pneumoniae isolates were penicillin resistant (penicillin MIC, ≥2 mg/liter) and 10.7% of enterococci (21.2% among E. faecium isolates) were vancomycin resistant. Omadacycline was active against Haemophilus influenzae (MIC50/90, 0.5/1 mg/liter) regardless of β-lactamase production and was active against Moraxella catarrhalis (MIC50/90, ≤0.12/0.25 mg/liter). Against Enterobacteriaceae, omadacycline was most active against Escherichia coli (MIC50/90, 1/2 mg/liter), Klebsiella oxytoca (MIC50/90, 1/4 mg/liter), and Enterobacter cloacae (MIC50/90, 2/4 mg/liter). Omadacycline had potent in vitro activity against Gram-positive and Gram-negative pathogens isolated from China and Taiwan and retained activity against problem pathogens, such as MRSA, vancomycin-resistant enterococci (VRE), penicillin-resistant S. pneumoniae (PRSPN), and extended-spectrum β-lactamase-producing E. coli The observed MIC profile in Chinese isolates was very similar to that seen in the U.S. and European surveillance studies.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Staphylococcus aureuszzm321990; Streptococcus pneumoniaezzm321990; aminomethylcycline; community-acquired pneumonia; skin and soft tissue infections; tetracyclines

Mesh:

Substances:

Year:  2019        PMID: 30617092      PMCID: PMC6395890          DOI: 10.1128/AAC.02262-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  In vitro activity of omadacycline against pathogens isolated from Mainland China during 2017-2018.

Authors:  Dong Dong; Yonggui Zheng; Qingqing Chen; Yan Guo; Yang Yang; Shi Wu; Demei Zhu; Daniel Deng; Patricia A Bradford; Harald Reinhart; Fupin Hu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-04-30       Impact factor: 3.267

2.  Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018.

Authors:  Michael A Pfaller; Michael D Huband; Dee Shortridge; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

3.  Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects.

Authors:  Haijing Yang; Zhiwei Huang; Yuancheng Chen; Yusong Zhu; Guoying Cao; Jingjing Wang; Yan Guo; Jicheng Yu; Jufang Wu; Lichuan Liu; Jun Deng; Jing Liu; Harald Reinhart; Jing Zhang; Xiaojie Wu
Journal:  Front Pharmacol       Date:  2022-04-21       Impact factor: 5.988

4.  Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data.

Authors:  Elizabeth A Lakota; Scott A Van Wart; Michael Trang; Evan Tzanis; Sujata M Bhavnani; M Courtney Safir; Lawrence Friedrich; Judith N Steenbergen; Paul G Ambrose; Christopher M Rubino
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

5.  Novel Tetracyclines Versus Alternative Antibiotics for Treating Acute Bacterial Infection: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Shao-Huan Lan; Wei-Ting Lin; Shen-Peng Chang; Li-Chin Lu; Chih-Cheng Lai; Jui-Hsiang Wang; Chien-Ming Chao
Journal:  Antibiotics (Basel)       Date:  2019-11-22

6.  Molecular Characterization of Staphylococcus aureus Obtained from Blood Cultures of Paediatric Patients Treated in a Tertiary Care Hospital in Mexico.

Authors:  Guillermo Jose Vazquez-Rosas; Jocelin Merida-Vieyra; Gerardo Aparicio-Ozores; Antonino Lara-Hernandez; Agustin De Colsa; Alejandra Aquino-Andrade
Journal:  Infect Drug Resist       Date:  2021-04-21       Impact factor: 4.003

7.  Activity of Omadacycline Alone and in Combination against Carbapenem-Nonsusceptible Acinetobacter baumannii with Varying Minocycline Susceptibility.

Authors:  Taylor Abbey; Alesia Vialichka; Michele Jurkovic; Mark Biagi; Eric Wenzler
Journal:  Microbiol Spectr       Date:  2022-06-01

8.  The efficacy and safety of omadacycline in treatment of acute bacterial infection: A systemic review and meta-analysis of randomized controlled trials.

Authors:  Shao-Huan Lan; Shen-Peng Chang; Chih-Cheng Lai; Li-Chin Lu; Chien-Ming Chao
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

9.  Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study.

Authors:  Meng Xiao; Jing-Jing Huang; Ge Zhang; Wen-Hang Yang; Fanrong Kong; Timothy Kudinha; Ying-Chun Xu
Journal:  BMC Microbiol       Date:  2020-11-16       Impact factor: 3.605

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.